Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Other Non Operating Income (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Other Non Operating Income for 14 consecutive years, with -$10.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 672.66% to -$10.5 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$14.4 million, a 378.06% decrease, with the full-year FY2025 number at -$965.0, down 100.03% from a year prior.
  • Other Non Operating Income was -$10.5 million for Q4 2025 at PharmaCyte Biotech, down from -$121.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $3.3 million in Q2 2024 to a low of -$10.5 million in Q4 2025.
  • A 5-year average of -$481361.5 and a median of -$249.0 in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: surged 239184.97% in 2024, then crashed 39238.52% in 2025.
  • PharmaCyte Biotech's Other Non Operating Income stood at $25097.0 in 2021, then crashed by 119.78% to -$4964.0 in 2022, then surged by 84.59% to -$765.0 in 2023, then soared by 239184.97% to $1.8 million in 2024, then tumbled by 672.66% to -$10.5 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Other Non Operating Income are -$10.5 million (Q4 2025), -$121.0 (Q3 2025), and -$113.0 (Q2 2025).